Two-thirds of advanced non-small cell lung cancer patients from a de-identified real-world database between 2011 and 2019 had evidence of adherence to National Comprehensive Cancer Network (NCCN)-recommended biomarker testing and first-line therapy based on biomarker testing.

Adherence to NCCN-recommended biomarker testing was associated with significantly lower risk of mortality among these patients.

Patients adherent to NCCN-recommended first-line therapy based on biomarker results had significantly lower risk of treatment discontinuation versus non-adherent patients.

The findings of this real-world data study demonstrate that, even among a large, heterogeneous population across the US, where testing and drug availability may differ, testing guidelines drive treatment decisions, resulting in a reduced risk of mortality and a moderate, yet significant, increased duration of treatment, collectively supporting the practice of precision medicine.